NASDAQ:APTX - Aptinyx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.50
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Aptinyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.67
▲ +233.33% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $11.67, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 233.33% upside from the last price of $3.50.

Buy

The current consensus among 9 investment analysts is to buy stock in Aptinyx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021HC WainwrightReiterated RatingBuy$8.00High
i
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
i
11/19/2020HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $8.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/13/2020SVB LeerinkLower Price TargetOutperform$14.00 ➝ $12.00High
i
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$9.00 ➝ $12.00High
i
10/27/2020Piper SandlerInitiated CoverageOverweight$10.00Low
i
10/21/2020CowenReiterated RatingBuyMedium
i
10/20/2020SVB LeerinkBoost Price TargetOutperform$12.00 ➝ $14.00Low
i
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
i
10/1/2020William BlairReiterated RatingBuyLow
i
Rating by M. Minter at William Blair
8/14/2020BMO Capital MarketsReiterated RatingBuy$13.00Medium
i
7/1/2020SunTrust BanksInitiated CoverageBuy$15.00High
i
6/18/2020HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2020William BlairInitiated CoverageOutperformMedium
i
Rating by M. Minter at William Blair
4/29/2020HC WainwrightInitiated CoverageBuy$7.00High
i
Rating by R. Selvaraju at HC Wainwright
11/14/2019CowenReiterated RatingBuyHigh
i
9/12/2019WedbushInitiated CoverageOutperform$7.00High
i
Rating by L. Chico at Wedbush
8/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
6/20/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
i
Rating by M. Goodman at SVB Leerink LLC
6/10/2019CowenReiterated RatingBuyHigh
i
4/30/2019Cantor FitzgeraldReiterated RatingBuyLow
i
Rating by Charles Duncan at Cantor Fitzgerald
3/22/2019BMO Capital MarketsReiterated RatingOutperformHigh
i
Rating by Gary Nachman at BMO Capital Markets
3/22/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
1/18/2019BMO Capital MarketsLower Price TargetOutperform$18.00Low
i
1/17/2019SVB LeerinkLower Price TargetOutperform$35.00 ➝ $22.00High
i
Rating by G. Porges at SVB Leerink LLC
1/17/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $8.00High
i
1/16/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
i
Rating by C. Duncan at Cantor Fitzgerald
12/3/2018Cantor FitzgeraldReiterated RatingBuy$40.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$40.00High
i
Rating by C. Duncan at Cantor Fitzgerald
7/16/2018SVB LeerinkInitiated CoverageOutperform$35.00Low
i
Rating by G. Porges at SVB Leerink LLC
7/16/2018CowenInitiated CoverageOutperformHigh
i
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$30.00Low
i
7/16/2018BMO Capital MarketsInitiated CoverageOutperform$32.00Low
i
(Data available from 6/14/2016 forward)
Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $3.50
$3.40
$3.70

50 Day Range

MA: $2.72
$2.39
$3.50

52 Week Range

Now: $3.50
$2.30
$6.47

Volume

3,746,810 shs

Average Volume

835,402 shs

Market Capitalization

$238.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Aptinyx?

The following sell-side analysts have issued research reports on Aptinyx in the last year: BMO Capital Markets, Cantor Fitzgerald, Cowen Inc, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, SunTrust Banks, Inc., SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for APTX.

What is the current price target for Aptinyx?

6 Wall Street analysts have set twelve-month price targets for Aptinyx in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 241.1%. SunTrust Banks, Inc. has the highest price target set, predicting APTX will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Aptinyx in the next year.
View the latest price targets for APTX.

What is the current consensus analyst rating for Aptinyx?

Aptinyx currently has 1 sell rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTX will outperform the market and that investors should add to their positions of Aptinyx.
View the latest ratings for APTX.

What other companies compete with Aptinyx?

How do I contact Aptinyx's investor relations team?

Aptinyx's physical mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company's listed phone number is 847-871-0377 and its investor relations email address is [email protected] The official website for Aptinyx is www.aptinyx.com.